No decision from EU drug regulator yet on Wegovy label expansion https://ift.tt/x3qRs9S

The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) would review Wegovy this week for possible wider use to include reducing the risk of strokes and heart attacks. Novo submitted applications to both the EMA and the U.S. Food and Drug Administration (FDA) for a label expansion after trial data published in August showed Wegovy had a clear cardiovascular benefit for overweight and obese people with a history of heart disease. The FDA has not issued its decision.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/51Ctec2